Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H-1337 in POAG or Ocular Hypertension
NCT03452033Phase 2Completed
- Sponsor
- Allysta Pharmaceuticals
- Start
- Mar 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of H-1337 in primary open-angle glaucoma (POAG), ocular hypertension, sponsored by Allysta Pharmaceuticals. Started Mar 2018; status: completed.
02
Drugs
H-1337
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT03452033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03452033.